Skip to main content

Medical Education Nursing Contact Us

Home
Find a Doctor
Find a Location
Services
Patients and Visitors
MyChart Login

Search

Services

Spartanburg Regional Healthcare System is dedicated to providing patient-centered care to communities we serve. Explore the wide range of services we offer.

Frequently Visited Services

Behavioral Health
Breast Health
Cancer
Emergency
Heart

Hospice
Imaging
Immediate Care
Maternity
Pharmacy

Rehabilitation
Spine
Sports Medicine Institute
Telehealth
Weight Loss

Patients and Visitors

Whether you’re seeking care or visiting a loved one, Spartanburg Regional Healthcare System is here for you. Our compassionate team provides the resources and support you need so you can focus on what is important.

Patients

Advance Directives
Chaplain Services
ER Wait Times
Language Services
Medical Records
MyChart Help and Information
Patient Rights
Planning Discharge
Pre-admission Testing (PAT)
Recognize Your Caregiver
When to Go Where

Visitors

Directions & Maps
Gift Shops
Hotel Information
Visitor Guidelines
Volunteer
Wireless Internet

Financial

Bill Pay
Financial Assistance Program
Insurance Information
Pricing Policies
No Surprises Act

Find a Doctor
Find a Location
Services
Patients and Visitors
MyChart Login
Medical Education
Nursing
Contact Us

Search

Menu

Search

Clinical Research Trials

Search by Name

(-) Accepting Participants
(-) Complete
Clear all filters

Status

Closed
(-) Accepting Participants
(-) Complete
In Progress

Disease Site

Oncology
Symptom Management & Cancer Control
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Thoracic Cancer
Hematologic Cancer
Cardiology
Precision Medicine & Rare Tumors
Cancer Care Delivery Research (CCDR)
Gynecologic Cancer
Neurologic Cancer
Phase 1
Cutaneous & Sarcoma Cancer
Head & Neck Cancer
Nephrology
Orthopaedic
Other
Wound Healing - Infectious Disease

Study Type

Treatment
Observational

Oncology

Oncology

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma (A071702)
Accepting Participants
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients With Resectable Brain Metastases (BN-012)
Accepting Participants
Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations (A031701)
Accepting Participants
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
Complete
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps, FORTE (NRG-CC005)
Accepting Participants
Germ Cell Tumor, Pediatric and Adult Patients (COG AGCT1531)
Accepting Participants
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (EAQ202)
Accepting Participants
Myopenia and Mechanism of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study (WF-1806)
Accepting Participants
NCI Community Oncology Research Program (NCORP) Tissue Procurement Protocol: An NCI Cancer MoonshotSM Study
Accepting Participants
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)(NRG-GU009)
Accepting Participants
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (NRG-GU010)
Accepting Participants
Optimizing Endocrine Therapy Adherence Through Motivational Interviewing and Text Interventions (GETSET) (A191901)
Accepting Participants
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (A031803)
Accepting Participants
Disparities in Results of Immune Checkpoint Inhibitor Treatment (DIRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/antiPD-L1 Immunotherapy in a Community Oncology Setting (URCC-21038)
Accepting Participants
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)
Complete
AMG 510 in Combination with Carboplatin and Pemetrexed or with Docetaxel in Subjects with NSCLC with KRAS p.G12C Mutation (Amgen Subprotocol F)
Accepting Participants
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast (ES2018-07)
Complete

Cutaneous & Sarcoma Cancer

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
Accepting Participants

Symptom Management & Cancer Control

Blinded Reference Set for Multicancer Early Detection Blood Tests (A212102)
Accepting Participants
Ovarian, Fallopian Tube, and Primary Peritoneal, Diet & Physical Activity (GOG-0225)
Complete
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue (URCC 18007)
Accepting Participants
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (NRG-CC008)
Accepting Participants
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy (S2205)
Accepting Participants
High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients (URCC-22053 VIPER)
Accepting Participants
An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study (URCC-22063)
Accepting Participants
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors (NRG-CC011)
Accepting Participants
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy (WF-2201)
Accepting Participants
Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers (WF-2301CD)
Accepting Participants
All Disease Sites; Health Disparities (DCP-001)
Accepting Participants
Colorectal Cancer, Cognitive Impairment (URCC 16092)
Complete

Breast Cancer

Breast Cancer Survivors, Cognitive Impairment, (REMEMBER) (WF 97116)
Complete
Breast Cancer, Young Women, Pregnancy Outcomes (POSITIVE) (A221405)
Complete
Triple Negative Breast Cancer (RX-5902)
Complete
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
Accepting Participants
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (AFT-58)
Accepting Participants
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases (S2007)
Accepting Participants
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (NSABP B-62 CAMBRIA-1)
Accepting Participants
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration (ORIC 114-01)
Accepting Participants
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial (A011801)
Accepting Participants
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (CCTG MA.39)
Accepting Participants
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (NRG BR009)
Accepting Participants

Cancer Care Delivery Research (CCDR)

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
Accepting Participants
Implementation and Effectiveness Trial of HN-STAR (WF-1805CD)
Accepting Participants
Prophylactic Colony Stimulating Factor Management, (S1415CD)
Complete

Hematologic Cancer

Lymphoma, Diffuse Large B-Cell, Relapsed or Refractory (1562-201)
Complete
Plasmacytoma of the Bone (A061402)
Complete

Precision Medicine & Rare Tumors

Lymphoma, Diffuse Large B-Cell, Treatment Naïve (DB102-02)
Complete
Leukemia, Chronic Myeloid (S1712)
Complete
Lymphoma, Mantle Cell, Previously Treated (AFT-32)
Complete

Thoracic Cancer

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (S1827)
Accepting Participants
Non-small Cell Lung Cancer (NSCLC), Metastatic (NRG LU-002)
Complete
Non-small Cell Lung Cancer ALCHEMIST (A151216)
Accepting Participants
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Accepting Participants
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer (NRG-LU008)
Accepting Participants

Gastrointestinal Cancer

Pancreatic Adenocarcinoma, Metastatic (ABI-007-PANC009)
Complete
Pancreatic Adenocarcinoma, Metastatic (NLG2104)
Complete
Pancreatic Cancer, Metastatic (RX-3117)
Complete
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (NRG-GI008)
Accepting Participants
Cholangiocarcinoma, Nonresectable or Metastatic IDH1 Mutation (AG120-C-005)
Complete
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer (A022104)
Accepting Participants

Genitourinary Cancer

Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial (NRG LU007)
Accepting Participants
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (S1806)
Closed
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer (NRG-GU013)
Accepting Participants

Head & Neck Cancer

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer (NRG HN005)
Accepting Participants

Other

Nephrology

Clinical Evaluation of a Vascular Venous Anastomotic Connector (02532621) (Phraxis InterGraft Study)
Complete

Wound Healing - Infectious Disease

MUSC MUSTCOOL: Prevent Ulcer Recurrence
Complete

Cardiology

National Cardiogenic Shock Initiative
Complete
The PEERLESS Study
Complete
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS (Dal-GenE-2 DAL-302)
Accepting Participants
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistula Study (VENO-CIP002 SAVE)
Accepting Participants

Orthopaedic

BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears (CSP-BB0003)
Accepting Participants

Oncology

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients with Advanced Solid Tumors (LSTA1-P02 BOLSTER)
Accepting Participants

ABOUT US

Board of Trustees
Community Health
Diversity and Inclusion
Media Policy
Mission and Vision

News - Discover Health
Policies
Quality
Social Media Guidelines
Spartanburg Regional Healthcare System History
Spartanburg Regional Healthcare System Museum
The Spartanburg Community

RESOURCES

Careers
Employees
Price Transparency
Information for Vendors
Integrity Hotline

Medical Staff Services
Project SEARCH
Safety and Awareness
Sponsorship
Health Library
Transfer Center
Transportation Services
Volunteer

IMPORTANT LINKS

Apella Health Management
Discover Health
Regional HealthPlus
Southeastern Health Partners
Spartanburg Regional Foundation

© 2025 Spartanburg Regional Healthcare System. All Rights Reserved.